Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lord, C. J.
Right arrow Articles by Ashworth, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lord, C. J.
Right arrow Articles by Ashworth, A.
Clinical Cancer Research Vol. 12, 4463-4468, August 1, 2006
© 2006 American Association for Cancer Research


Molecular Pathways

Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy

Christopher J. Lord1, Michelle D. Garrett2 and Alan Ashworth1

Authors' Affiliations: 1 The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom and 2 Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom

Requests for reprints: Alan Ashworth, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, United Kingdom. Phone: 44-20-7153-5333; Fax: 44-20-7153-5340; E-mail: alan.ashworth{at}icr.ac.uk.

Abstract

DNA repair pathways are crucial for the maintenance of genome integrity. The pathway that repairs DNA double-strand breaks (DSB) has components involved in both signaling and repairing DNA damage. Impairing DSB repair using specific inhibitors of signaling or repair might, in principle, sensitize tumor cells to particular DNA-damaging agents. Moreover, the existence of specific defects in DNA repair pathways in tumors provides the rationale for the use of "synthetic lethal" approaches targeting this cellular "Achilles' heel." Here, we discuss the mechanisms involved in DSB repair and detail potential therapeutic approaches based on targeting this pathway.




This article has been cited by other articles:


Home page
Genes Dev.Home page
D. A. Mordes, G. G. Glick, R. Zhao, and D. Cortez
TopBP1 activates ATR through ATRIP and a PIKK regulatory domain
Genes & Dev., June 1, 2008; 22(11): 1478 - 1489.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
H. L. Ball, M. R. Ehrhardt, D. A. Mordes, G. G. Glick, W. J. Chazin, and D. Cortez
Function of a Conserved Checkpoint Recruitment Domain in ATRIP Proteins
Mol. Cell. Biol., May 1, 2007; 27(9): 3367 - 3377.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Ratnam and J. A. Low
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Clin. Cancer Res., March 1, 2007; 13(5): 1383 - 1388.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2006 by the American Association for Cancer Research.